While this study emphasizes the efficacy of SGLT-2 inhibitors as monotherapy, there is a pressing need to investigate the optimal combination of SGLT-2 inhibitors with other HF medications (such as ACE inhibitors, β-blockers, and aldosterone antagonists). This evidence concerns the gene ACE and hydrops fetalis.